Alzheimer's Disease - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Alzheimer's Disease - Pipeline Review, H1 2019’, provides an overview of the Alzheimer's Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alzheimer's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Alzheimer's Disease

- The report reviews pipeline therapeutics for Alzheimer's Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Alzheimer's Disease therapeutics and enlists all their major and minor projects

- The report assesses Alzheimer's Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Alzheimer's Disease

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

2A Pharma AB

4D Pharma Plc

AB Science SA

AbbVie Inc

AC Immune SA

Actinogen Medical Ltd

Acumen Pharmaceuticals Inc

Addex Therapeutics Ltd

Affichem SA ...

2A Pharma AB

4D Pharma Plc

AB Science SA

AbbVie Inc

AC Immune SA

Actinogen Medical Ltd

Acumen Pharmaceuticals Inc

Addex Therapeutics Ltd

Affichem SA

AFFiRiS AG

Alector Inc

AlfaSigma SpA

Allergan Plc

Allgenesis Biotherapeutics Inc

ALSP Inc

AlzeCure Pharma AB

Alzheon Inc

Alzhyme Pty Ltd

Alzinova AB

AlzProtect SAS

Amarantus Bioscience Holdings Inc

Amgen Inc

Anavex Life Sciences Corp

Aphios Corp

Apodemus AB

Applied Research using OMIC Sciences SL

Araclon Biotech SL

Archer Pharmaceuticals Inc

ArmaGen Inc

Artery Therapeutics Inc

Arvinas Inc

Asceneuron SA

Astellas Pharma Inc

AstraZeneca Plc

Auritec Pharmaceuticals Inc

Avanir Pharmaceuticals Inc

Avineuro Pharmaceuticals Inc

Axon Neuroscience SE

Axsome Therapeutics Inc

Axxam SpA

AZTherapies Inc

BCWorld Pharm Co Ltd

Beactica AB

Berg LLC

BioArctic AB

Biogen Inc

Biohaven Pharmaceutical Holding Company Ltd

BioHealthonomics Inc

BioXcel Therapeutics Inc

Boehringer Ingelheim GmbH

Bolder Biotechnology Inc

Boryung Pharmaceutical Co Ltd

Bristol-Myers Squibb Co

Bsim2

Cantabio Pharmaceuticals Inc

Carna Biosciences Inc

Cassava Sciences Inc

Celon Pharma SA

Center Laboratories Inc

Cerecin Inc

CHA Bio & Diostech Co Ltd

Chong Kun Dang Pharmaceutical Corp

Clera Inc

CMG Pharmaceutical Co Ltd

Cognition Therapeutics Inc

Cognosci Inc

CohBar Inc

Corium International Inc

Cortice Biosciences Inc

Cotinga Pharmaceuticals Inc

Crossbeta Biosciences BV

CTD Holdings Inc

Cypralis Ltd

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

DanPET AB

Daval International Ltd

Denali Therapeutics Inc

Diffusion Pharmaceuticals Inc

Dong Wha Pharma Co Ltd

Dongkook Pharmaceutical Co Ltd

Eisai Co Ltd

Eli Lilly and Co

Endece LLC

Epigen Biosciences Inc

F. Hoffmann-La Roche Ltd

Fujifilm Toyama Chemical Co Ltd

Fulcrum Therapeutics Inc

GemVax & KAEL Co Ltd

Genentech Inc

Genervon Biopharmaceuticals LLC

GeneScience Pharmaceuticals Co Ltd

GlaxoSmithKline Plc

GliaCure Inc

Glialogix Inc

Golden Biotechnology Corp

Grifols SA

H. Lundbeck AS

Hana Pharm Co Ltd

Hemostemix Inc

HitGen LTD

HSRx Group

ICB International Inc

Icure Pharmaceutical Inc

ID Pharma Co Ltd

Immungenetics AG

Immunwork Inc

Impel NeuroPharma Inc

Inflazome Ltd

Inmune Bio Inc

Instituto Biomar SA

Insys Therapeutics Inc

Intra-Cellular Therapies Inc

Io Therapeutics Inc

Ionis Pharmaceuticals Inc

Jeil Pharmaceutical Co Ltd

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

K-Stemcell Co Ltd

Kadmon Corp LLC

Kalgene Pharmaceuticals Inc

Karuna Therapeutics Inc

Kyowa Hakko Kirin Co Ltd

Lead Discovery Center GmbH

Les Laboratoires Servier SAS

Lipopharma Therapeutics SL

Living Cell Technologies Ltd

Lupin Ltd

M3 Biotechnology Inc

ManRos Therapeutics

MedDay SA

Medesis Pharma SA

MedImmune LLC

MEDRx Co Ltd

MeiraGTx Holdings Plc

Merck & Co Inc

MetrioPharm AG

MGC Pharmaceuticals Ltd

Mission Therapeutics Ltd

ModGene Pharma LLC

Montisera Ltd

NAL Pharmaceuticals Ltd

Nanna Therapeutics Ltd

Nanomerics Ltd

NatureWise Biotech & Medicals Corp

NeoNeuro SAS

Neuralstem Inc

Neurim Pharmaceuticals Ltd

Neuro Bio Ltd

Neuro-Sys SAS

Neurodyn Life Sciences Inc

NeuroGeneration Inc

NeuroGenetic Pharmaceuticals Inc

NeuroNascent Inc

NeurOp Inc

Neuropore Therapies Inc

NeuroScientific Biopharmaceuticals Ltd

Neurotez Inc

New World Laboratories Inc

NoNO Inc

Novartis AG

Nymox Pharmaceutical Corp

Ono Pharmaceutical Co Ltd

Oryzon Genomics SA

Ovensa Inc

Oxstem Ltd

P2D Inc

Panorama Research Inc

Peptron Inc

Pharmasum Therapeutics AS

Pharnext SA

Phoenix Biotechnology Inc

Prevacus Inc

Priavoid GmbH

Probiodrug AG

Progenra Inc

ProMIS Neurosciences Inc

Proteome Sciences Plc

Prothena Corp Plc

QR Pharma Inc

Quimatryx SL

Regenera Pharma Ltd

reMYND NV

ReNetX Bio

Revalesio Corp

Rodin Therapeutics Inc

Rodos BioTarget GmbH

Sage Therapeutics Inc

Samjin Pharm Co Ltd

Samumed LLC

Sangamo Therapeutics Inc

Sanofi

SBI Pharmaceuticals Co Ltd

Sentinel Oncology Ltd

Serometrix LLC

Shionogi & Co Ltd

Simcere Pharmaceutical Group

Sosei Heptares

Spherium Biomed SL

Summit Therapeutics Plc

Suven Life Sciences Ltd

T3D Therapeutics Inc

Takeda Pharmaceutical Co Ltd

TechnoPhage SA

Teikoku Pharma USA Inc

Telocyte LLC

Tetra Discovery Partners LLC

Teva Pharmaceutical Industries Ltd

Tonix Pharmaceuticals Holding Corp

Treventis Corp

UCB SA

United Neuroscience Ltd

Varinel Inc

Virobay Inc

Voyager Therapeutics Inc

vTv Therapeutics Inc

Vybion Inc

Xigen SA

Zensun (Shanghai) Sci & Tech Co Ltd

Zhejiang Hisun Pharmaceutical Co Ltd

ZZ Biotech LLC

Table of Contents

Table of Contents

Table of Contents

Introduction

Alzheimer's Disease – Overview

Alzheimer's Disease – Therapeutics Development

Alzheimer's Disease – Therapeutics Assessment

Alzheimer's Disease – Companies ...

Table of Contents

Table of Contents

Introduction

Alzheimer's Disease – Overview

Alzheimer's Disease – Therapeutics Development

Alzheimer's Disease – Therapeutics Assessment

Alzheimer's Disease – Companies Involved in Therapeutics Development

Alzheimer's Disease – Drug Profiles

Alzheimer's Disease – Dormant Projects

Alzheimer's Disease – Discontinued Products

Alzheimer's Disease – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Alzheimer's Disease, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products ...

List of Tables

Number of Products under Development for Alzheimer's Disease, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Alzheimer's Disease – Pipeline by 2A Pharma AB, H1 2019

Alzheimer's Disease – Pipeline by 4D Pharma Plc, H1 2019

Alzheimer's Disease – Pipeline by AB Science SA, H1 2019

Alzheimer's Disease – Pipeline by AbbVie Inc, H1 2019

Alzheimer's Disease – Pipeline by AC Immune SA, H1 2019

Alzheimer's Disease – Pipeline by Actinogen Medical Ltd, H1 2019

Alzheimer's Disease – Pipeline by Acumen Pharmaceuticals Inc, H1 2019

Alzheimer's Disease – Pipeline by Addex Therapeutics Ltd, H1 2019

Alzheimer's Disease – Pipeline by Affichem SA, H1 2019

Alzheimer's Disease – Pipeline by AFFiRiS AG, H1 2019

Alzheimer's Disease – Pipeline by Alector Inc, H1 2019

Alzheimer's Disease – Pipeline by AlfaSigma SpA, H1 2019

Alzheimer's Disease – Pipeline by Allergan Plc, H1 2019

Alzheimer's Disease – Pipeline by Allgenesis Biotherapeutics Inc, H1 2019

Alzheimer's Disease – Pipeline by ALSP Inc, H1 2019

Alzheimer's Disease – Pipeline by AlzeCure Pharma AB, H1 2019

Alzheimer's Disease – Pipeline by Alzheon Inc, H1 2019

Alzheimer's Disease – Pipeline by Alzhyme Pty Ltd, H1 2019

Alzheimer's Disease – Pipeline by Alzinova AB, H1 2019

Alzheimer's Disease – Pipeline by AlzProtect SAS, H1 2019

Alzheimer's Disease – Pipeline by Amarantus Bioscience Holdings Inc, H1 2019

Alzheimer's Disease – Pipeline by Amgen Inc, H1 2019

Alzheimer's Disease – Pipeline by Anavex Life Sciences Corp, H1 2019

Alzheimer's Disease – Pipeline by Aphios Corp, H1 2019

Alzheimer's Disease – Pipeline by Apodemus AB, H1 2019

Alzheimer's Disease – Pipeline by Applied Research using OMIC Sciences SL, H1 2019

Alzheimer's Disease – Pipeline by Araclon Biotech SL, H1 2019

Alzheimer's Disease – Pipeline by Archer Pharmaceuticals Inc, H1 2019

Alzheimer's Disease – Pipeline by ArmaGen Inc, H1 2019

Alzheimer's Disease – Pipeline by Artery Therapeutics Inc, H1 2019

Alzheimer's Disease – Pipeline by Arvinas Inc, H1 2019

Alzheimer's Disease – Pipeline by Asceneuron SA, H1 2019

Alzheimer's Disease – Pipeline by Astellas Pharma Inc, H1 2019

Alzheimer's Disease – Pipeline by AstraZeneca Plc, H1 2019

Alzheimer's Disease – Pipeline by Auritec Pharmaceuticals Inc, H1 2019

Alzheimer's Disease – Pipeline by Avanir Pharmaceuticals Inc, H1 2019

Alzheimer's Disease – Pipeline by Avineuro Pharmaceuticals Inc, H1 2019

Alzheimer's Disease – Pipeline by Axon Neuroscience SE, H1 2019

Alzheimer's Disease – Pipeline by Axsome Therapeutics Inc, H1 2019

Alzheimer's Disease – Pipeline by Axxam SpA, H1 2019

Alzheimer's Disease – Pipeline by AZTherapies Inc, H1 2019

Alzheimer's Disease – Pipeline by BCWorld Pharm Co Ltd, H1 2019

Alzheimer's Disease – Pipeline by Beactica AB, H1 2019

List of Figures

List of Figures

Number of Products under Development for Alzheimer's Disease, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products ...

List of Figures

Number of Products under Development for Alzheimer's Disease, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports